Jing Jing

1.5k total citations · 2 hit papers
41 papers, 922 citations indexed

About

Jing Jing is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Jing Jing has authored 41 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 20 papers in Molecular Biology and 11 papers in Immunology. Recurrent topics in Jing Jing's work include Cancer Immunotherapy and Biomarkers (10 papers), Cancer Genomics and Diagnostics (4 papers) and Nanoplatforms for cancer theranostics (4 papers). Jing Jing is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Cancer Genomics and Diagnostics (4 papers) and Nanoplatforms for cancer theranostics (4 papers). Jing Jing collaborates with scholars based in China, United States and Australia. Jing Jing's co-authors include Xiujing He, Hubing Shi, Xiaowei Liu, Xuelei Ma, Yangfu Jiang, Yunuo Zhao, Ting Luo, Xi Wu, Yujie Zhao and Jinen Song and has published in prestigious journals such as Advanced Materials, SHILAP Revista de lepidopterología and Biomaterials.

In The Last Decade

Jing Jing

36 papers receiving 907 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance

2023 217 citations Xiaowei Liu, Jinen Song et al. Cancer Cell profile →
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine

2022 202 citations Xiujing He, Xiaowei Liu et al. profile →

Peers

Countries citing papers authored by Jing Jing

Since Specialization

Citations

This map shows the geographic impact of Jing Jing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing Jing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing Jing more than expected).

Fields of papers citing papers by Jing Jing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jing Jing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing Jing. The network helps show where Jing Jing may publish in the future.

Co-authorship network of co-authors of Jing Jing

This figure shows the co-authorship network connecting the top 25 collaborators of Jing Jing. A scholar is included among the top collaborators of Jing Jing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing Jing. Jing Jing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Promotion of triple negative breast cancer immunotherapy by combining bioactive radicals with immune checkpoint blockade 2025 ·Acta Biomaterialia ·Meixu Chen, Linlin Song, Ruhong Zhou, Tianyue Xu, Ting Sun, Zhihui Liu, Zihan Xu, (unknown), Peixin Du, Yingying Ma, Li‐Wen Huang, Xiaoting Chen, Guang Yang, Jing Jing, Hubing Shi	5
2	Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy 2025 ·MedComm ·(unknown), Jing Jing	0
3	Unraveling the underlying mechanisms of cancer stem cells in therapeutic resistance for optimizing treatment strategies 2025 ·SHILAP Revista de lepidopterología ·(unknown), Siyuan Qin, Zhe Zhang, (unknown), Li Zhou, Bowen Li, Edouard C. Nice, Yuanyuan Zhang, Jing Jing	8
4	Stimuli-responsive polymer-dasatinib prodrug to reprogram cancer-associated fibroblasts for boosted immunotherapy 2025 ·Journal of Controlled Release ·Yuxin Zhang, (unknown), (unknown), (unknown), Yunkun Li, (unknown), Guohao Liu, Qiyong Gong, Kui Luo, Jing Jing	7
5	A cisplatin prodrug-based self-assembling ozone delivery nanosystem sensitizes radiotherapy in triple-negative breast cancer 2025 ·Acta Pharmaceutica Sinica B ·(unknown), (unknown), Meixu Chen, Linlin Song, Zhihui Liu, Cheng Yan, (unknown), Li‐Wen Huang, Xingwen Li, (unknown), Cong Li, (unknown), Jing Jing, Hubing Shi	0
6	Single-cell transcriptional dissection illuminates an evolution of immunosuppressive microenvironment during pancreatic ductal adenocarcinoma metastasis 2025 ·Signal Transduction and Targeted Therapy ·Xiaowei Liu, Jinen Song, (unknown), (unknown), Huihui Li, (unknown), Xinmin Wang, Xueyan Wang, Qian Xiao, Li Li, Xinyu Liu, (unknown), Jian‐Lin Wu, Jing Jing, Xuelei Ma, Hubing Shi	2
7	Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy 2025 ·Science Advances ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hao Wang, (unknown), (unknown), (unknown), Jing Jing, Ying Zhang, Juan Xu, (unknown), (unknown)	5
8	Blockade of metastasis by targeting circulating tumor cells with platelet encapsuled oncolytic adenovirus 2025 ·Biomaterials ·(unknown), Linlin Song, Xin Wang, Ruhong Zhou, Meixu Chen, Tianyue Xu, Li‐Wen Huang, Yingying Ma, Zihan Xu, (unknown), (unknown), Dan Luo, (unknown), Xiaoting Chen, Guang Yang, (unknown), (unknown), (unknown), Jing Jing, Hubing Shi	0
9	Galectin-9-driven immunosuppressive macrophage population shapes the lymph node metastatic microenvironment 2025 ·British Journal of Cancer ·Yao Zhou, Xiaowei Liu, (unknown), Genpeng Li, Xiujing He, (unknown), Xueyan Wang, (unknown), Jianyong Lei, Jing Jing, Hubing Shi	0
10	Overview of Artificial Intelligence in Breast Cancer Medical Imaging 2023 ·Journal of Clinical Medicine ·(unknown), Xiujing He, Jing Jing	45
11	Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance breakdown → 2023 ·Cancer Cell ·Xiaowei Liu, Jinen Song, Hao Zhang, Xinyu Liu, (unknown), Yunuo Zhao, Yujie Zhao, Xiaomeng Yin, Xinyu Guo, Xi Wu, Hu Zhang, Jie Xu, Jianping Hu, Jing Jing, Xuelei Ma, Hubing Shi	217
12	Artificial Intelligence-Assisted Transcriptomic Analysis to Advance Cancer Immunotherapy 2023 ·Journal of Clinical Medicine ·Yu Gui, Xiujing He, Jing Yu, Jing Jing	11
13	Protocol for identifying immune checkpoint on circulating tumor cells of human pancreatic ductal adenocarcinoma by single-cell RNA sequencing 2023 ·STAR Protocols ·Xiaowei Liu, Jinen Song, Xinyu Liu, Hao Zhang, Xueyan Wang, (unknown), (unknown), Jing Jing, Xuelei Ma, Hubing Shi	4
14	PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer 2022 ·Cell Reports Medicine ·Xueyan Wang, Jing Yu, Xiaowei Liu, Dan Luo, (unknown), Linlin Song, Xian Jiang, Xiaomeng Yin, Yan Wang, Li Chai, Ting Luo, Jing Jing, Hubing Shi	20
15	Microbiota and their metabolites potentiate cancer immunotherapy: Therapeutic target or resource for small molecule drug discovery? 2022 ·Frontiers in Pharmacology ·Peixin Du, Jing Jing, Xiujing He	5
16	The Evolution of Acquired Resistance to BRAFV600E kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling 2021 ·Journal of Investigative Dermatology ·Guangchao Xu, Ya Luo, Wenshuang Wu, Xiaowei Liu, (unknown), Yu Bao, Xiujing He, Jing Yu, Yanna Li, Jiqiao Yang, Rongjie Zhang, Chune Yu, Hongying Chen, (unknown), (unknown), Jing Jing, Hubing Shi	15
17	Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer 2021 ·Oncogene ·Chune Yu, Dan Luo, Jing Yu, Min Zhang, Xiaobo Zheng, Guangchao Xu, (unknown), Huiling Wang, Yufei Xu, (unknown), (unknown), Xuelei Ma, Jing Jing, Hubing Shi	52
18	Long Non-coding RNA BTG3-7:1 and JUND Co-regulate C21ORF91 to Promote Triple-Negative Breast Cancer Progress 2021 ·Frontiers in Molecular Biosciences ·(unknown), Xiujing He, Ting Luo, Xiaorong Zhong, Hong Zheng, Jiqiao Yang, (unknown), Jing Jing	7
19	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations 2019 ·Frontiers in Pharmacology ·Jiqiao Yang, Xiujing He, Qing Lv, Jing Jing, Hubing Shi	21
20	Treatment and survival patterns of Chinese patients diagnosed with breast cancer between 2005 and 2009 in Southwest China 2016 ·Medicine ·(unknown), Wei Jia, Xuesong Lu, Hong Zheng, Xiaorong Zhong, Weiguo Gao, Yunqin Chen, Jing Jing	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact